Head and neck cancer surgeon Bhuvanesh Singh commented on a paper that found that the number of cases of thyroid cancer in the United States tripled from 1973 to 2009, largely due to more aggressive screening techniques and improved imaging.
Medical oncologist Robert Motzer discussed a study he led that showed that the drug pazopanib works as well as sunitinib for treating advanced kidney cancer.
Prostate cancer surgeon Peter Scardino weighed in on a new study that has reignited a debate about whether men should use a baldness drug to prevent prostate cancer.
Cell researcher Michel Sadelain demonstrated that cancer-targeted immune cells can be grown in the lab from stem cells and that when infused into tumor-bearing mice, are able to attack cancer cells and suppress tumor growth.
A study led by thoracic surgeon Prasad Adusumilli found that an abnormal cell pattern identified in the tumor tissue of some lung cancer patients may help to predict which tumors are more likely to recur after surgery.
Infectious diseases specialist Eric Pamer commented on the discovery of a new bacterium responsible for cord colitis, a syndrome that affects a small number of patients treated with umbilical cord stem cells for blood cancer and other hematologic diseases.
Epidemiologist Peter Bach commented on draft recommendations from the US Preventive Services Task Force on screening for lung cancer, and Memorial Sloan-Kettering’s lung cancer screening decision tool was highlighted.
Medical oncologist Larry Norton commented on recommendations from a working group of the National Cancer Institute that suggested changing the definition of cancer.
Primary care physician Kevin Oeffinger discussed the need for cancer patients to receive guidance and continual follow-up care after their treatment is done.
